AIMS: Endocrine therapy is a pivotal treatment for women with hormone-receptor positive breast cancer. In premenopausal women, endocrine therapy primarily consists of tamoxifen and ovarian suppressive strategies. Younger women experience improvements in the risks of relapse or death from breast cancer with the use of chemotherapy as well, with part of this benefit explained by resultant premature amenorrhea. Unfortunately despite a centuries worth of clinical trials, the most efficacious combination of hormonal therapies and chemotherapy has yet to be determined. This paper serves as a comprehensive review of the substantial data in the adjuvant treatment of premenopausal, hormone receptor-positive women with breast cancer. METHODS AND RESULTS: PubMed and American Society of Clinical Oncology (ASCO) Proceedings searches from 1896 to present were performed. All of the trials examining the role of ovarian suppression and tamoxifen with and without chemotherapy in premenopausal women were included. The current data suggests that endocrine therapy can be an important alternative to chemotherapy in select patient populations, and improvements in outcome are also seen with the combination of hormonal and chemotherapy strategies in other populations. A majority of the trials examined did not use what is considered to be current standards of care regarding chemotherapy regimens and durations of adjuvant hormonal therapy. Many unanswered questions remain particularly regarding the combined use of ovarian suppression and tamoxifen in women who are also receiving chemotherapy. CONCLUSION: There is a persistent need to define optimal endocrine therapy in premenopasusal women with hormone-receptor positive breast cancer. Contemporaneous trials, such as the SOFT trial will provide direction, and additional biomarker and pharmacogenomic data will further supplement individualized patient decision making.
AIMS: Endocrine therapy is a pivotal treatment for women with hormone-receptor positive breast cancer. In premenopausal women, endocrine therapy primarily consists of tamoxifen and ovarian suppressive strategies. Younger women experience improvements in the risks of relapse or death from breast cancer with the use of chemotherapy as well, with part of this benefit explained by resultant premature amenorrhea. Unfortunately despite a centuries worth of clinical trials, the most efficacious combination of hormonal therapies and chemotherapy has yet to be determined. This paper serves as a comprehensive review of the substantial data in the adjuvant treatment of premenopausal, hormone receptor-positive women with breast cancer. METHODS AND RESULTS: PubMed and American Society of Clinical Oncology (ASCO) Proceedings searches from 1896 to present were performed. All of the trials examining the role of ovarian suppression and tamoxifen with and without chemotherapy in premenopausal women were included. The current data suggests that endocrine therapy can be an important alternative to chemotherapy in select patient populations, and improvements in outcome are also seen with the combination of hormonal and chemotherapy strategies in other populations. A majority of the trials examined did not use what is considered to be current standards of care regarding chemotherapy regimens and durations of adjuvant hormonal therapy. Many unanswered questions remain particularly regarding the combined use of ovarian suppression and tamoxifen in women who are also receiving chemotherapy. CONCLUSION: There is a persistent need to define optimal endocrine therapy in premenopasusal women with hormone-receptor positive breast cancer. Contemporaneous trials, such as the SOFT trial will provide direction, and additional biomarker and pharmacogenomic data will further supplement individualized patient decision making.
Authors: F Boccardo; A Rubagotti; D Amoroso; M Mesiti; D Romeo; P Sismondi; M Giai; F Genta; P Pacini; V Distante; A Bolognesi; D Aldrighetti; A Farris Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: M Andersson; C Kamby; M B Jensen; H Mouridsen; B Ejlertsen; P Dombernowsky; C Rose; S Cold; M Overgaard; J Andersen; M Kjaer Journal: Eur J Cancer Date: 1999-11 Impact factor: 9.162
Authors: J G Klijn; L V Beex; L Mauriac; J A van Zijl; C Veyret; J Wildiers; J Jassem; M Piccart; J Burghouts; D Becquart; C Seynaeve; F Mignolet; L Duchateau Journal: J Natl Cancer Inst Date: 2000-06-07 Impact factor: 13.506
Authors: T Delozier; M Spielmann; J Macé-Lesec'h; M Janvier; C Hill; B Asselain; J P Julien; B Weber; L Mauriac; J C Petit; P Kerbrat; J P Malhaire; P Vennin; B Leduc; M Namer Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: P E Goss; J N Ingle; S Martino; N J Robert; H B Muss; R B Livingston; N E Davidson; E A Perez; Y Chavarri-Guerra; D A Cameron; K I Pritchard; T Whelan; L E Shepherd; D Tu Journal: Ann Oncol Date: 2012-10-01 Impact factor: 32.976
Authors: Theresa H M Keegan; David J Press; Li Tao; Mindy C DeRouen; Allison W Kurian; Christina A Clarke; Scarlett L Gomez Journal: Breast Cancer Res Date: 2013 Impact factor: 6.466